Lakhasly

Lung cancer is the world's leading cause of cancer death, with a low 5-year survival rate (16%) in the US, despite treatment advancements. Lung cancer patients often have comorbid lung illnesses, increasing their risk of exercise intolerance and impaired pulmonary function, especially after surgery or chemo-radiation. Performance status is crucial for treatment decisions, sometimes precluding therapy. Concomitant respiratory disease exacerbates lung toxicity from chemo- or radiotherapy. Breathlessness significantly impacts quality of life. Simple nursing interventions like relaxation and breathing exercises improve performance status and overall well-being, suggesting pulmonary rehabilitation (PR) is beneficial. However, evidence supporting PR for lung cancer patients is limited to specific clinical situations.

Lung cancer is the leading cause of cancer death in the world , In the United States, the overall 5-year survival rate of lung cancer is 16% , Survival has improved with advances in treatment modalities. Given the high incidence of comorbid lung illness observed in lung cancer patients, patients are particularly at risk for exercise intolerance and impaired pulmonary function in the setting of both surgery and chemo-radiation , Performance status is an essen- tial determining factor in therapeutic decisions and in some cases can exclude a patient from receiving any therapy. In addition, concomitant chronic respiratory disease contrib- utes to a higher incidence of lung toxicity in patients receiving chemo- or radiotherapy which may aggravate respiratory symptoms ,
Breathlessness affects quality of life. Minimal nursing interventions such as relaxation and breathing exercises have been shown to improve performance status, and physical and emotional states , Hence, PR is a good intervention for these patients with chronic lung disease. Evidence supporting the benefits of PR in patients with lung cancer is limited to certain clinical settings.